‘Goldilocks’ binding strength determines anti-cancer T-cell efficacy and fate
Immunotherapy, treatments that reinvigorate immune cells’ anti-cancer activity or reprogram T cells to target cancer, has shown promise in treating leukemias but has not yet been realized in solid tumors. One reason for the stymied success is the conversion of potential cancer-killing T cells into an inactive “exhausted” state near the tumor. St. Jude Children’s … Read more
